01 Dec 2023
1 December 2023 Changes to the PBS Listings of Medicines for the Treatment of Ankylosing Spondylitis
On 1 December 2023, changes will be made to the authority requirements of the following biological medicines listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of ankylosing spondylitis – adalimumab, etanercept and infliximab.
22 Nov 2023
Agenda for the March 2024 PBAC meeting – 22 November 2023
Agenda for the March 2024 PBAC meeting – 22 November 2023
22 Nov 2023
Updates to the HTA Review Research and Analysis papers collection: Draft HTA expert paper published
Updates to the HTA Review Research and Analysis papers collection: Draft HTA expert paper published
16 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee – 16 November 2023
Updates to the HTA Policy and Methods Review Reference Committee – 16 November 2023
10 Nov 2023
Updates to the HTA Review: Consultation 1 report published
Updates to the HTA Review: Consultation 1 report published
09 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee – 9 November 2023
Updates to the HTA Policy and Methods Review Reference Committee – 9 November 2023
06 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee – 3 November 2023
Updates to the HTA Policy and Methods Review Reference Committee – 3 November 2023
01 Nov 2023
PBS arrangements during shortage of amoxicillin and clavulanate potassium 400 mg/57 mg per 5 mL oral suspension effective 1 November 2023
Due to the shortage of Curam Duo (amoxicillin 400 mg/5 mL + clavulanic acid 57 mg/5 mL powder for oral liquid, 60 mL)
30 Oct 2023
Updates to the HTA Review Research and analysis papers collection: Draft HTA expert paper published - 30 October 2023
The draft paper International Health Technology Market Approval, Funding and Assessment Pathways developed to support the deliberations of the HTA Review Reference Committee, has been published on the HTA Review Research and Analysis papers webpage.